These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30802411)

  • 1. Ibrutinib-associated Serositis in Mantle Cell Lymphoma.
    Styskel BA; Lopez-Mattei J; Jimenez CA; Stewart J; Hagemeister FB; Faiz SA
    Am J Respir Crit Care Med; 2019 Jun; 199(12):e43-e44. PubMed ID: 30802411
    [No Abstract]   [Full Text] [Related]  

  • 2. Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.
    Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Nishikawa T
    J Clin Exp Hematop; 2019; 59(2):98-100. PubMed ID: 31257351
    [No Abstract]   [Full Text] [Related]  

  • 3. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
    Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Bothos J; Goldberg JD; Enny C; Traina S; Balasubramanian S; Bandyopadhyay N; Sun S; Vermeulen J; Rizo A; Rule S
    Lancet; 2016 Feb; 387(10020):770-8. PubMed ID: 26673811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.
    Tucker DL; Naylor G; Kruger A; Hamilton MS; Follows G; Rule SA
    Br J Haematol; 2017 Jul; 178(2):327-329. PubMed ID: 27197509
    [No Abstract]   [Full Text] [Related]  

  • 5. Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report.
    Kaur V; Swami A
    J Oncol Pharm Pract; 2017 Apr; 23(3):235-239. PubMed ID: 26970573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience.
    Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
    Cancer Med; 2019 Nov; 8(16):6860-6870. PubMed ID: 31560165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Staphylococcus aureus meningitis in a patient with mantle cell lymphoma under treatment with ibrutinib.
    Diamantopoulos PT; Psichogiou M; Pantazatou A; Zervakis K; Rougala N; Giannakopoulou N; Daikos G; Viniou NA
    Ann Hematol; 2017 Jun; 96(6):1049-1050. PubMed ID: 28247056
    [No Abstract]   [Full Text] [Related]  

  • 8. [Mantle cell lymphoma of the iris treated by ibrutinib].
    Sales De Gauzy T; Oberic L; Fournié P; Soler V
    J Fr Ophtalmol; 2018 Dec; 41(10):e501-e502. PubMed ID: 30449641
    [No Abstract]   [Full Text] [Related]  

  • 9. Ibrutinib approved for mantle cell lymphoma.
    Cancer Discov; 2014 Jan; 4(1):OF1. PubMed ID: 24402946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib (Imbruvica). Relapsed chronic lymphocytic leukaemia and mantle cell lymphoma: uncertain impact on survival.
    January
    Prescrire Int; 2016 Apr; 25(170):89-92. PubMed ID: 27183765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma.
    Lee HJ; Schmelz JL; Cramer F; Romaguera JE; Badillo M; Wang M
    Br J Haematol; 2020 Mar; 188(6):e94-e98. PubMed ID: 32057090
    [No Abstract]   [Full Text] [Related]  

  • 12. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis.
    Rule S; Dreyling M; Goy A; Hess G; Auer R; Kahl B; Hernández-Rivas JÁ; Qi K; Deshpande S; Parisi L; Wang M
    Haematologica; 2019 May; 104(5):e211-e214. PubMed ID: 30442728
    [No Abstract]   [Full Text] [Related]  

  • 13. Ibrutinib--a new standard treatment for relapsed mantle cell lymphoma?
    Martin P
    Lancet; 2016 Feb; 387(10020):728-9. PubMed ID: 26673812
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment response of cutaneous mantle cell lymphoma to ibrutinib and radiotherapy.
    Mancebo SE; Smith JR; Intlekofer AM; Zelenetz AD; Myskowski PL
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e113-5. PubMed ID: 25499623
    [No Abstract]   [Full Text] [Related]  

  • 15. [Ibrutinib: A new drug of B-cell malignancies].
    Thieblemont C
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
    Kim ES; Dhillon S
    Drugs; 2015 May; 75(7):769-76. PubMed ID: 25802231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperleukocytosis increases risk of fatal hyperkalemia with new ibrutinib/venetoclax regimen for refractory mantle cell lymphoma.
    Verma A; Mbughuni M; Mariash E; Mesa H
    J Chemother; 2019; 31(7-8):428-431. PubMed ID: 31738653
    [No Abstract]   [Full Text] [Related]  

  • 18. Ibrutinib for the treatment of mantle cell lymphoma.
    Shah N; Hutchinson C; Rule S
    Expert Rev Hematol; 2014 Oct; 7(5):521-31. PubMed ID: 25158606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
    Prescrire Int; 2016 Apr; 25(170):91. PubMed ID: 27186618
    [No Abstract]   [Full Text] [Related]  

  • 20. Haematological cancer: Ibrutinib paves way to a brighter future in MCL.
    Killock D
    Nat Rev Clin Oncol; 2016 Feb; 13(2):65. PubMed ID: 26718106
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.